SCHEMBL29673262

SCHEMBL29673262

CN1CCc2cc(CN)ccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.51
MAPT P10636 3/20 0.51
ALDH1A1 P00352 3/20 0.51
MEN1 O00255 2/20 0.51
GAA P10253 2/20 0.51
TP53 P04637 2/20 0.51
LMNA P02545 2/20 0.51
KDM4E B2RXH2 1/20 0.51
CASP1 P29466 1/20 0.51
HTT P42858 1/20 0.51
CASP7 P55210 1/20 0.51
SMAD3 P84022 1/20 0.51
HSD17B10 Q99714 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
PDE10A Q9Y233 1/20 0.45
WDR5 P61964 1/20 0.43
HPGD P15428 1/20 0.41
NOTUM Q6P988 2/20 0.40
CHRNA7 P36544 1/20 0.40
PRMT6 Q96LA8 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13603607 1.00 KMT2A (0.51) KMT2AMAPTALDH1A1MEN1GAA
SCHEMBL31020834 0.90 ALDH1A1 (0.59) KMT2AMAPTALDH1A1MEN1GAA
SCHEMBL31020835 0.90 ALDH1A1 (0.59) KMT2AMAPTALDH1A1MEN1GAA
SCHEMBL1076966 0.90 ALDH1A1 (0.59) KMT2AMAPTALDH1A1MEN1GAA
SCHEMBL13203632 0.84 SRD5A1 (0.49) KMT2AMAPTALDH1A1MEN1GAA
SCHEMBL25144468 0.82 PDE10A (0.45) KMT2AMAPTALDH1A1MEN1GAA
SCHEMBL13263654 0.81 HTR2C (0.50) KMT2AMAPTALDH1A1MEN1GAA
SCHEMBL113802 0.79 KDM4E (0.41) KMT2AMAPTALDH1A1MEN1GAA
SCHEMBL13233322 0.79 PDE10A (0.43) KMT2AMAPTALDH1A1MEN1GAA
SCHEMBL26242100 0.78 LMNA (0.56) MAPTALDH1A1LMNAKDM4ECHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4635568-A2 COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES ACADIA Pharmaceuticals Inc. (US) 2025-10-22 EP disclosed
EP-3672954-B1 COMPOUNDS, SALTS THEREOF AND THEIR USE FOR THE TREATMENT OF DISEASES ACADIA PHARM INC (US) 2025-08-13 EP disclosed
US-20250197385-A1 COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES ACADIA PHARM INC (US) 2025-06-19 US disclosed
US-12139477-B2 Compounds, salts thereof and methods for treatment of diseases ACADIA PHARMACEUTICALS INC. (US) 2024-11-12 US disclosed
US-20220298151-A1 COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES ACADIA PHARMACEUTICALS INC. (US) 2022-09-22 US disclosed
US-11345693-B2 Compounds, salts thereof and methods for treatment of diseases ACADIA PHARMACEUTICALS INC. (US) 2022-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220298151-A1 COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES SLC10A1, CYP27A1, CYP11B2 KMT2A 3811/4885MAPT 1125/4885ALDH1A1 240/4885
US-12139477-B2 Compounds, salts thereof and methods for treatment of diseases SLC10A1, CYP27A1, CYP11B2 KMT2A 3811/4885MAPT 1125/4885ALDH1A1 240/4885
US-11345693-B2 Compounds, salts thereof and methods for treatment of diseases SLC10A1, CYP27A1, CYP11B2 KMT2A 3811/4885MAPT 1125/4885ALDH1A1 240/4885
US-20250197385-A1 COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES SLC10A1, CYP27A1, CYP11B2 KMT2A 3811/4885MAPT 1125/4885ALDH1A1 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.